Chimerix (NASDAQ:CMRX – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $11.00 target price on the biopharmaceutical company’s stock. A number of other brokerages have also recently commented on CMRX. Robert W. Baird […]
Chimerix (NASDAQ:CMRX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by analysts at Wedbush in a research report issued to clients and investors on Wednesday, RTT News reports. They currently have a $6.00 price objective on the biopharmaceutical company’s stock. CMRX has been the topic of several other research reports. Robert W. Baird […]
Chimerix, Inc. (NASDAQ:CMRX – Get Rating) saw a large drop in short interest in the month of May. As of May 15th, there was short interest totalling 3,720,000 shares, a drop of 9.3% from the April 30th total of 4,100,000 shares. Approximately 5.0% of the company’s shares are sold short. Based on an average daily […]
Robert W. Baird assumed coverage on shares of Chimerix (NASDAQ:CMRX – Get Rating) in a research note issued to investors on Monday, The Fly reports. The brokerage issued an outperform rating and a $7.00 price objective on the biopharmaceutical company’s stock. Several other equities research analysts have also recently weighed in on the company. HC […]
Robert W. Baird assumed coverage on shares of Chimerix (NASDAQ:CMRX – Get Rating) in a report released on Monday, The Fly reports. The firm set an “outperform” rating on the biopharmaceutical company’s stock. Several other equities analysts have also issued reports on the company. StockNews.com started coverage on Chimerix in a research note on Thursday. […]